CD274 and neoplasm: This may be due to a varying role of PD-L1 as a prognostic factor (i.e., independent of treatment type), suggests the potential for differences between tumor types with respect to PD-L1–independent immune escape pathways, or may reflect differences in tumor heterogeneity, sample size, clinical stage, or the timepoint of PD-L1 measurement (37).